Rodgers Brothers Inc. Raises Holdings in Stryker Co. (NYSE:SYK)

Rodgers Brothers Inc. lifted its position in Stryker Co. (NYSE:SYK) by 14.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,217 shares of the medical technology company’s stock after acquiring an additional 150 shares during the quarter. Rodgers Brothers Inc.’s holdings in Stryker were worth $438,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the fourth quarter worth approximately $25,000. Dunhill Financial LLC raised its position in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker during the fourth quarter valued at about $30,000. Finally, BankPlus Trust Department purchased a new position in Stryker in the fourth quarter valued at about $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on SYK. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Barclays raised their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Argus set a $450.00 price target on Stryker in a research report on Monday, February 3rd. The Goldman Sachs Group set a $422.00 price objective on Stryker in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Stock Up 2.3 %

Shares of SYK opened at $372.73 on Tuesday. The company has a market capitalization of $142.27 billion, a price-to-earnings ratio of 48.03, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The stock’s 50-day moving average price is $383.86 and its 200-day moving average price is $374.41. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. On average, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.90%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.